Last update 29 Mar 2025

Technetium Tc-99M Apcitide

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals
Synonyms
AcuTect, Technetium Tc 99m apcitide, Technetium-99m apcitide
+ [2]
Action
antagonists
Mechanism
GP IIb/IIIa antagonists(Integrin alpha-IIb/beta-3 antagonists)
Therapeutic Areas
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseWithdrawn
First Approval Date
United States (14 Sep 1998),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC51H73N17NaO20S5Tc
InChIKeyZSGICUWBNPIMTG-AYDXVUFGSA-J
CAS Registry178959-14-3
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute deep vein thrombosis of lower limb
United States
14 Sep 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
73
(Pediatric patients aged 1-6 years)
tailgncdak(wibsgpvtuz) = pdoyunecnr qorzrsganp (vhniekdvke )
Positive
19 Nov 2018
(Pediatric patients aged 7-17 years)
tailgncdak(wibsgpvtuz) = uokwljktdq qorzrsganp (vhniekdvke )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free